2m 2m 2m 2m 2m 2m 2m
SENSEI BIOTHERP (SNSE)
NASDAQ
$15.92+$0.07 (+0.44%)
Price as of Jun 03, 2026 4:10 PM EDT- $28.4MMarket Cap
- 125.01%1-Year Change
- BiotechnologyIndustry
SENSEI BIOTHERP (SNSE)
$15.92+$0.07 (+0.44%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | 0 N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -11.0M -41.16% | -18.6M +1.79% | -18.3M -39.77% | -30.4M +35.64% | |
Depreciation and Amortization Expense | 122,000 -77.86% | 551,000 -3.50% | 571,000 -7.00% | 614,000 -10.36% | |
Total Operating Expenses | 22.3M -31.66% | 32.6M -12.01% | 37.1M -26.15% | 50.2M +33.90% | |
Operating Profit | -22.3M -31.66% | -32.6M -12.01% | -37.1M -26.15% | -50.2M +33.90% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | -32,000 -64.44% | -90,000 -37.50% | -144,000 -34.25% | -219,000 -67.31% | |
Interest Income and Expense and Net | -32,000 -64.44% | -90,000 -37.50% | -144,000 -34.25% | -219,000 -67.31% | |
Total Nonoperating Income and Expense | -4,000 +33.33% | -3,000 -98.60% | -215,000 -697.22% | 36,000 -94.63% | |
Income before Taxes | -21.1M -30.08% | -30.2M -11.57% | -34.1M -29.82% | -48.6M +32.05% | |
Income Taxes | 0 +100.00% | -7.2M -27.34% | -9.9M +22.95% | -8.0M -3.12% | |
Extraordinary Items | 0 -100.00% | 951,000 N/A | 0 N/A | 0 N/A | |
Net Income | -21.1M -30.08% | -30.2M -11.57% | -34.1M -29.82% | -48.6M +32.05% | |
Net Income from Continuing Operations Applicable to Common | -21.1M -30.08% | -30.2M -11.57% | -34.1M -29.82% | -48.6M +32.05% | |
Basic EPS and Net Income | -16.72 +1,293.33% | -1.20 -1.64% | -1.22 -22.78% | -1.58 +18.80% | |
Diluted EPS and Net Income | -16.72 +1,293.33% | -1.20 -1.64% | -1.22 -22.78% | -1.58 +18.80% | |
Basic Weighted Average Shares | 1.3M -94.98% | 25.1M -10.14% | 28.0M -8.96% | 30.7M +10.80% | |
Diluted Weighted Average Shares | 1.3M -94.98% | 25.1M -10.14% | 28.0M -8.96% | 30.7M +10.80% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 8.7M -13.27% | 10.0M -23.19% | 13.0M -26.88% | 17.8M +148.57% | |
Short-Term Investments | 12.5M -60.07% | 31.3M -40.58% | 52.7M -40.95% | 89.3M -36.41% | |
Cash and Cash Equivalents and Short-Term Investments | 21.2M -48.75% | 41.3M -37.14% | 65.8M -38.61% | 107.1M -27.44% | |
Total Current Assets | 21.5M -48.71% | 41.9M -37.65% | 67.3M -38.07% | 108.6M -26.90% | |
Accumulated Depreciation | 540,000 -63.90% | 1.5M -13.38% | 1.7M +19.76% | 1.4M +21.28% | |
Property and Plant and Equipment and Net | 82,000 -80.34% | 417,000 -64.21% | 1.2M -43.14% | 2.0M -55.88% | |
Total Long-Term Assets | 18,000 -62.50% | 48,000 -44.19% | 86,000 +36.51% | 63,000 +61.54% | |
Total Assets | 22.9M -49.51% | 45.4M -39.01% | 74.4M -37.17% | 118.4M -22.74% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 4.3M -21.97% | 5.4M -3.46% | 5.6M -37.76% | 9.1M +85.44% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 59,000 -11.94% | 67,000 0.00% | 67,000 -55.03% | 149,000 0.00% | |
Total Liabilities | 4.3M -38.21% | 7.0M -26.42% | 9.5M -36.67% | 15.0M +123.00% | |
Retained Earnings | -283.1M +8.05% | -262.1M +13.00% | -231.9M +17.24% | -197.8M +32.56% | |
Total Stockholders Equity | 18.6M -51.57% | 38.4M -40.85% | 64.9M -37.24% | 103.4M -29.42% | |
Total Shares Outstanding | 1.3M -94.99% | 25.2M +0.60% | 25.0M -18.64% | 30.8M +0.51% | |
Cash Flow | |||||
Cash from Operating Activities | -20.5M -17.09% | -24.7M -22.96% | -32.0M -17.94% | -39.0M +28.97% | |
Capital Expenditures | 16,000 -89.04% | 146,000 -18.89% | 180,000 -43.93% | 321,000 -84.16% | |
Cash from Investing Activities | 19.8M -11.89% | 22.4M -41.58% | 38.4M -23.10% | 49.9M +134.90% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -645,000 -18.04% | -787,000 -92.96% | -11.2M +3,793.03% | -287,000 -100.18% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -61.78% +22.64% | -50.37% +42.36% | -35.38% -1.10% | -35.78% N/A | |
Return on Equity | -74.01% +26.74% | -58.40% +44.11% | -40.52% +4.22% | -38.88% N/A | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 5.06 -34.26% | 7.70 -35.42% | 11.92 -0.50% | 11.98 N/A | |
Cash Ratio | 2.04 +11.15% | 1.83 -20.44% | 2.31 +17.47% | 1.96 N/A | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow